Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41375-020-01107-y http://scihub22266oqcxt.onion/10.1038/s41375-020-01107-y 33414483!7789078!33414483     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Leukemia 2021 ; 35 (2): 485-493 Nephropedia Template TP {{tp|p=33414483|t=2021. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib |pdf=|usr=}}{{33414483}} gab.com Text High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib JO: Leukemia http://www.kidney.de/pget.php?&tw=1&pmid=33414483 #FOAvip We report the clinical presentation and risk factors for survival in 175 patients with myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. After a median follow-up of 50 days, mortality was higher than in the general population and reached 48% in myelofibrosis (MF). Univariate analysis, showed a significant relationship between death and age, male gender, decreased lymphocyte counts, need for respiratory support, comorbidities and diagnosis of MF, while no association with essential thrombocythemia (ET), polycythemia vera (PV), and prefibrotic-PMF (pre-PMF) was found. Regarding MPN-directed therapy ongoing at the time of COVID-19 diagnosis, Ruxolitinib (Ruxo) was significantly more frequent in patients who died in comparison with survivors (p = 0.006). Conversely, multivariable analysis found no effect of Ruxo alone on mortality, but highlighted an increased risk of death in the 11 out of 45 patients who discontinued treatment. These findings were also confirmed in a propensity score matching analysis. In conclusion, we found a high risk of mortality during COVID-19 infection among MPN patients, especially in MF patients and/or discontinuing Ruxo at COVID-19 diagnosis. These findings call for deeper investigation on the role of Ruxo treatment and its interruption, in affecting mortality in MPN patients with COVID-19. Twit Text FOAVip High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib ????Leukemia http://www.kidney.de/pget.php?&tw=1&pmid=33414483 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33414483 #FOAvip English Wikipedia <ref>{{Cite pmid|33414483}}</ref> High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib #MMPMID33414483 Barbui T; Vannucchi AM; Alvarez-Larran A; Iurlo A; Masciulli A; Carobbio A; Ghirardi A; Ferrari A; Rossi G; Elli E; Andrade-Campos MM; Kabat MG; Kiladjian JJ; Palandri F; Benevolo G; Garcia-Gutierrez V; Fox ML; Foncillas MA; Morcillo CM; Rumi E; Osorio S; Papadopoulos P; Bonifacio M; Cervantes KSQ; Serrano MS; Carreno-Tarragona G; Sobas MA; Lunghi F; Patriarca A; Elorza BN; Angona A; Mazo EM; Koschmieder S; Ruggeri M; Cuevas B; Hernandez-Boluda JC; Abadia EL; Cirici BX; Guglielmelli P; Garrote M; Cattaneo D; Daffini R; Cavalca F; Bellosillo B; Benajiba L; Curto-Garcia N; Bellini M; Betti S; De Stefano V; Harrison C; Rambaldi A Leukemia 2021[Feb]; 35 (2): 485-493 PMID33414483show ga We report the clinical presentation and risk factors for survival in 175 patients with myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. After a median follow-up of 50 days, mortality was higher than in the general population and reached 48% in myelofibrosis (MF). Univariate analysis, showed a significant relationship between death and age, male gender, decreased lymphocyte counts, need for respiratory support, comorbidities and diagnosis of MF, while no association with essential thrombocythemia (ET), polycythemia vera (PV), and prefibrotic-PMF (pre-PMF) was found. Regarding MPN-directed therapy ongoing at the time of COVID-19 diagnosis, Ruxolitinib (Ruxo) was significantly more frequent in patients who died in comparison with survivors (p = 0.006). Conversely, multivariable analysis found no effect of Ruxo alone on mortality, but highlighted an increased risk of death in the 11 out of 45 patients who discontinued treatment. These findings were also confirmed in a propensity score matching analysis. In conclusion, we found a high risk of mortality during COVID-19 infection among MPN patients, especially in MF patients and/or discontinuing Ruxo at COVID-19 diagnosis. These findings call for deeper investigation on the role of Ruxo treatment and its interruption, in affecting mortality in MPN patients with COVID-19. |Aged[MESH] |COVID-19/complications/*mortality/transmission/virology[MESH] |Europe/epidemiology[MESH] |Female[MESH] |Follow-Up Studies[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Myeloproliferative Disorders/drug therapy/epidemiology/*mortality/virology[MESH] |Nitriles[MESH] |Prognosis[MESH] |Pyrazoles/*administration & dosage[MESH] |Pyrimidines[MESH] |Retrospective Studies[MESH] |SARS-CoV-2/*isolation & purification[MESH] |Survival Rate[MESH]High mortality rate in COVID-19 patients with myeloproliferative neopl(epmc).pdf DeepDyve Pubget Overpricing